Bioleap (Drug Discovery) Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Bioleap (Drug Discovery) General Information

Description

Developer of advanced multi-modal therapies designed to cure complex diseases. The company's platform integrates physics, biology, and artificial intelligence to model and predict therapeutic responses, enabling researchers in the immuno-oncology market to accelerate the discovery and development of new biologics.

Contact Information

Website
www.bioleap.ai
Formerly Known As
MPS Genesis
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Salisbury House, Station Road
  • Cambridge CB1 2LA
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Salisbury House, Station Road
  • Cambridge CB1 2LA
  • England, United Kingdom

Bioleap (Drug Discovery) Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bioleap (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator Completed Clinical Trials - Phase 3
3. Seed Round 26-Jul-2024 Completed Clinical Trials - Phase 3
2. Accelerator/Incubator 01-Jan-2023 $394K Completed Startup
1. Seed Round 05-Apr-2022 $394K $394K Completed Startup
To view Bioleap (Drug Discovery)’s complete valuation and funding history, request access »

Bioleap (Drug Discovery) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary
To view Bioleap (Drug Discovery)’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Bioleap (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bioleap (Drug Discovery) Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atlas SGR Asset Manager Minority
P4 Precision Accelerator/Incubator
SFC Capital Venture Capital Minority
West Midlands Health Tech Innovation Accelerator Accelerator/Incubator
To view Bioleap (Drug Discovery)’s complete investors history, request access »

Bioleap (Drug Discovery) FAQs

  • When was Bioleap (Drug Discovery) founded?

    Bioleap (Drug Discovery) was founded in 2022.

  • Where is Bioleap (Drug Discovery) headquartered?

    Bioleap (Drug Discovery) is headquartered in Cambridge, United Kingdom.

  • What is the size of Bioleap (Drug Discovery)?

    Bioleap (Drug Discovery) has 6 total employees.

  • What industry is Bioleap (Drug Discovery) in?

    Bioleap (Drug Discovery)’s primary industry is Drug Discovery.

  • Is Bioleap (Drug Discovery) a private or public company?

    Bioleap (Drug Discovery) is a Private company.

  • What is Bioleap (Drug Discovery)’s current revenue?

    The current revenue for Bioleap (Drug Discovery) is .

  • How much funding has Bioleap (Drug Discovery) raised over time?

    Bioleap (Drug Discovery) has raised $394K.

  • Who are Bioleap (Drug Discovery)’s investors?

    Atlas SGR, P4 Precision, SFC Capital, and West Midlands Health Tech Innovation Accelerator have invested in Bioleap (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process